Dive Brief:The Food and Drug Administration on Wednesday approved Yuvezzi, an eye drop Tenpoint Therapeutics developed for presbyopia. An $85 million Series B funding was led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. Tenpoint plans to launch Yuvezzi in the second quarter of 2026, Henric Bjarke, the company’s CEO, said in a statement. It’s the “first and only dual-agent” presbyopia drug that “offers the right balance of efficacy, tolerability and ease of use,” Bjarke wrote in an email to BioPharma Dive. But Tenpoint merged with a fellow eye drug developer called Visus Therapeutics in 2024 and switched up its leadership team.